Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases

Archives of Neurology

Volumn 56, Issue 6, 1999, Pages 661-663

  Stangel, Martin ^a   Toyka, Klaus V ^b   Gold, Ralf ^b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT;

DEMYELINATING DISEASE; DEMYELINATION; DOSE RESPONSE; DRUG MEGADOSE; GUILLAIN BARRE SYNDROME; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; POLYNEUROPATHY; PRIORITY JOURNAL; REMYELINIZATION; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TISSUE INJURY; VIRUS INFECTION;

EID: 0033040882     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.6.661     Document Type: Review

References (21)

1. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349:225-230.
2. Hahn AF, Botton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain. 1996;119:1067-1077.
3. Nobile-Orazio E. Multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 1996;60:599-603.
4. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, for the Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet. 1997;349:589-593.
5. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol. 1990;27:12-17.
6. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94:1729-1735.
7. Hartung H-P, Toyka KV, Griffin JW. Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. In: Antel J, Birnbaum G, Hartung H-P, eds. Clinical Neuroimmunology. Blackwell Science: Maiden, Mass; 1998; 294-306.
8. Lutz HU, Stammler P, Jelezarova E, Nater M, Spath PJ. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood. 1996;88: 184-193.
9. Kaveri S, Vassilev T, Hurez V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest. 1996;97:865-369.
10. 2+-dependent signal transduction through Fcg receptors in B lymphocytes. Scand J Immunol. 1994;40: 37-42.
11. Kazatchkine MD, Dietrich G, Hurez V, et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig). Immunol Rev. 1994; 139:79-107.
12. Debré M, Bonnet M-C, Fridman W-H, et al. Infusion of Fc-gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet. 1993; 342:945-949.
13. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 1999;340:227-228.
14. Miyagi F, Horiuchl H, Nagata I, et al. Fc portion of intravenous immunoglobulins suppresses the induction of experimental allergic neuritis. J Neuroimmunol. 1997; 78:127-131.
15. Silvestris F, D'Amore O, Cafforio P, Savino L, Dammacco F. Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG. Clin Exp Immunol. 1996;104(suppl 1):91-97.
16. van Doorn PA, Brand A, Vermeulen M. Anti-neuroblastoma cell line antibodies in inflammatory demyelinating polyneuropathy: inhibition in vitro and in vivo by IV immunoglobulin. Neurology. 1988;38:1592-1595.
17. Andersson J, Skansén-Saphir U, Sparrelid E, Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol. 1996;104(suppl 1):10-20.
18. Ross C, Svenson M, Hansen MB, Vejlsgaard GL, Bendtzen K. High avidity IFN-neutrallzing antibodies in pharmaceutically prepared human IgG. J Clin Invest. 1995;95:1974-1978.
19. Stangel M, Schumacher HC, Ruprecht K, Boegner F, Marx P. Immunoglobulins for intravenous use inhibit TNF α cytotoxicity in vitro. Immunol Invest. 1997;26: 569-578.
20. Pavelko KD, van Engelen BGM, Rodriguez M. Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination. J Neurosci. 1998;18:2498-2505.
21. Dalakas MC, Quartes RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 1996;40:792-795.